You are here: Industry Insights > Samsung

News List

Moderna, Samsung Biologics sign agreement for fill-finish manufacturing of COVID-19 vaccine expresspharma
May 24, 2021
The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish manufacturing service.
Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration contractpharma
April 28, 2021
Samsung Biologics, a contract development and manufacturing organization (CDMO) and TG Therapeutics, are expanding a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.
Samsung BioLogics Expands Biomanufacturing Capabilities contractpharma
August 13, 2019
Implements large scale N-1 perfusion for commercial application.
Samsung honors three teams with the breakthrough innovations biospectrumasia
August 08, 2019
Samsung Electronics America, Inc., presented three teams – SAIF, Key Watch and Crowd Aid with the Breakthroughs that Matter Award on the final day of the MIT Hacking Medicine Grand Hack in Washington, D.C.
Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal contractpharma
August 01, 2019
The CDMO will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy.
FDA approves Samsung Bioepis’ Humira biosimilar pharmaceutical-technology
July 26, 2019
South Korea-based Samsung Bioepis has received approval from the US Food and Drug Administration (FDA) for Hadlima, a biosimilar to Abbvie’s Humira (adalimumab) treatment.
Samsung’s new smart watch has blood pressure function pharmaphorum
February 26, 2019
Samsung has followed the example of Apple and launched a smart watch with a focus on improving the wearer’s health.
FDA approves Samsung/Merck & Co’s Herceptin biosimilar pharmaphorum
January 23, 2019
The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.
Samsung Bioepis, 3SBio partner to expand biosimilar business in China biospectrumasia
January 07, 2019
Samsung Bioepis Co., Ltd. has announced that its rapidly growing biosimilar business will expand into mainland China through a licensing agreement with 3SBio Inc.
Samsung and Bioepis launch third Humira biosimilar in Europe pharmafile
October 19, 2018
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.

Previous page 1 2 3 4 Next page